Table 3.

Clinical outcome measures at follow-up 1.

Outcome variable	Mean (SD)	Difference to baseline	95% Confidence interval		t-statistic (df)	p-value	Effect size (η2)
			Lower bound	Upper bound
FBS (mmol/L)
Control group	12.09 ± 1.34	−2.54	11.87	12.31	12.51 (1, 297)	<0.001	0.34
Intervention group	10.01 ± 1.51	−4.50	9.77	10.25
RBS (mmol/L)
Control group	15.86 ± 0.58	−1.74	15.76	15.95	25.32 (1, 297)	<0.001	0.68
Intervention group	12.96 ± 1.24	−4.96	12.77	13.16
HbA1c (%)
Control group	10.38 ± 1.10	−0.92	10.20	10.56	4.82 (1, 297)	<0.001	0.07
Intervention group	9.83 ± 0.85	−1.58	9.70	9.97
BP systolic (mmHg)
Control group	133.99 ± 3.29	−3.55	133.44	134.53	−1.89 (1, 297)	0.059	0.01
Intervention group	134.77 ± 3.80	−4.49	134.17	135.37
BP diastolic (mmHg)
Control group	85.15 ± 5.05	−1.51	84.31	85.99	2.66 (1, 297)	0.008	0.02
Intervention group	83.45 ± 5.87	−3.76	82.52	84.38
T. Cholesterol (mmol/L)
Control group	5.59 ± 0.43	−0.44	5.52	5.67	4.04 (1, 297)	<0.001	0.05
Intervention group	5.41 ± 0.32	−0.75	5.36	5.47
Triglyceride (mmol/L)
Control group	1.88 ± 0.18	−0.13	1.85	1.91	−3.54 (1, 297)	<0.001	0.04
Intervention group	1.96 ± 0.21	−0.10	1.93	2.00
LDL-C (mmol/L)
Control group	2.73 ± 0.12	−0.08	2.71	2.75	−8.67 (1, 297)	<0.001	0.20
Intervention group	3.01 ± 0.35	−0.86	2.95	3.06
HDL-C (mmol/L)
Control group	1.16 ± 0.03	+0.12	1.15	1.16	7.69 (1, 297)	<0.001	0.16
Intervention group	1.12 ± 0.05	+0.12	1.11	1.12

p-value between both study groups after 6 months of baseline. Two-way ANOVA was used to find the p-values (Post-hoc analysis using the Games-Howell procedure). The t-statistic is further from zero than the critical values considered to reject the Null Hypothesis. C.I, confidence interval (group statistics); SD, standard deviation; df, degrees of freedom. The effect size was measured by Partial Eta Squared (η²). According to Cohen’s classification of effect size, if 0.01 ≤ η² ≤ 0.06 = small, if 0.06 ≤ η² ≤ 0.14 = medium, η² ≥ 0.14 = large.